A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML

The response rate of non-M3 AML to all trans retinoic acid (ATRA) has been limited. Using Affymetrix expression arrays, we found that in diverse AML blasts RXRA was expressed at higher levels than RARA and that mouse Ctsg-PML-RARA leukemia responded to bexarotene, a ligand for RXRA. We therefore per...

詳細記述

保存先:
書誌詳細
主要な著者: Welch, John S., Niu, Haixia, Uy, Geoffrey L., Westervelt, Peter, Abboud, Camille N., Vij, Ravi, Stockerl-Goldstein, Keith E., Jacoby, Meagan, Pusic, Iskra, Schroeder, Mark A., Dipersio, John F., Cashen, Amanda F.
フォーマット: Artigo
言語:Inglês
出版事項: 2014
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4108244/
https://ncbi.nlm.nih.gov/pubmed/24723466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23735
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料